Literature DB >> 23239905

Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.

Matteo Garcovich, Maria Assunta Zocco, Davide Roccarina, Francesca Romana Ponziani, Antonio Gasbarrini.   

Abstract

The gut flora plays an important role in the pathogenesis of the complications of cirrhosis. Hepatic encephalopathy (HE) represents a broad continuum of neuropsychological dysfunction in patients with acute or chronic liver disease and/or porto-systemic shunting of blood flow and it manifests with progressive deterioration of the superior neurological functions. The pathophysiology of this disease is complex, as it involves overproduction and reduced metabolism of various neurotoxins, particularly ammonia. Management of HE is diversified and requires several steps: elimination of precipitating factors, removal of toxins, proper nutritional support, modulation of resident fecal flora and downregulation of systemic and gut-derived inflammation. This review will provide an overview of gut barrier function and the influence of gut-derived factors on HE, focusing on the role of gut microbiota in the pathogenesis of HE and the recent literature findings on its therapeutic manipulation.

Entities:  

Keywords:  Cirrhosis; Gut microbiota; Hepatic encephalopathy; Non-absorbable disaccharides; Rifaximin

Mesh:

Substances:

Year:  2012        PMID: 23239905      PMCID: PMC3520156          DOI: 10.3748/wjg.v18.i46.6693

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

1.  Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.

Authors:  Tarek Hassanein; Andres T Blei; William Perry; Robin Hilsabeck; Jan Stange; Fin S Larsen; Robert S Brown; Stephen Caldwell; Brendan McGuire; Frederik Nevens; Robert Fontana
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

2.  Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Authors:  Antoni Mas; Juan Rodés; Lourdes Sunyer; Luís Rodrigo; Ramon Planas; Victor Vargas; Lluís Castells; Dolores Rodríguez-Martínez; Conrado Fernández-Rodríguez; Ignasi Coll; Albert Pardo
Journal:  J Hepatol       Date:  2003-01       Impact factor: 25.083

3.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

4.  Patients with autonomic neuropathy are more likely to develop hepatic encephalopathy.

Authors:  Anurag Maheshwari; Anil Thomas; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

Review 5.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

6.  Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.

Authors:  G Pedretti; C Calzetti; G Missale; F Fiaccadori
Journal:  Ital J Gastroenterol       Date:  1991-05

7.  Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

Authors:  Barjesh Chander Sharma; Praveen Sharma; Amit Agrawal; Shiv Kumar Sarin
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

8.  Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.

Authors:  E Strauss; R Tramote; E P Silva; W R Caly; N Z Honain; R A Maffei; M F de Sá
Journal:  Hepatogastroenterology       Date:  1992-12

9.  Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.

Authors:  Carroll B Leevy; James A Phillips
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

10.  Management of hepatic encephalopathy.

Authors:  G Wright; A Chattree; R Jalan
Journal:  Int J Hepatol       Date:  2011-09-21
View more
  20 in total

Review 1.  Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.

Authors:  Ming Luo; Jian-Yang Guo; Wu-Kui Cao
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 2.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

Review 3.  Brain edema in acute liver failure: mechanisms and concepts.

Authors:  Kakulavarapu V Rama Rao; Arumugam R Jayakumar; Michael D Norenberg
Journal:  Metab Brain Dis       Date:  2014-02-25       Impact factor: 3.584

Review 4.  Immune mechanisms in acetaminophen-induced acute liver failure.

Authors:  Oliver Krenkel; Jana C Mossanen; Frank Tacke
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

5.  Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes.

Authors:  Leigh C Casadaban; Ahmad Parvinian; Jeet Minocha; Janesh Lakhoo; Christopher W Grant; Charles E Ray; M Grace Knuttinen; James T Bui; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

Review 6.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

7.  Increased toll-like receptor 4 in cerebral endothelial cells contributes to the astrocyte swelling and brain edema in acute hepatic encephalopathy.

Authors:  Arumugam R Jayakumar; Xiao Y Tong; Kevin M Curtis; Roberto Ruiz-Cordero; Maria T Abreu; Michael D Norenberg
Journal:  J Neurochem       Date:  2013-11-22       Impact factor: 5.372

Review 8.  Gut microbiota and host metabolism in liver cirrhosis.

Authors:  Makoto Usami; Makoto Miyoshi; Hayato Yamashita
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 9.  Gut biogeography of the bacterial microbiota.

Authors:  Gregory P Donaldson; S Melanie Lee; Sarkis K Mazmanian
Journal:  Nat Rev Microbiol       Date:  2015-10-26       Impact factor: 60.633

10.  Race and Gradient Difference Are Associated with Increased Risk of Hepatic Encephalopathy Hospital Admission After Transjugular Intrahepatic Portosystemic Shunt Placement.

Authors:  Michael W Rowley; Myunghan Choi; Steve Chen; Kevin Hirsch; Anil B Seetharam
Journal:  J Clin Exp Hepatol       Date:  2017-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.